https://www.phenomixsciences.com https://www.phenomixsciences.com/evidence https://www.phenomixsciences.com/platform https://www.phenomixsciences.com/company/meet-the-team https://www.phenomixsciences.com/company/media-and-press https://www.phenomixsciences.com/partners https://www.phenomixsciences.com/company/our-story https://www.phenomixsciences.com/contact https://www.phenomixsciences.com/privacy-policy https://www.phenomixsciences.com/terms-of-service https://www.phenomixsciences.com/fcoi https://www.phenomixsciences.com/white-paper/precision-medicine-in-obesity-applying-oncologys-lessons-to-transform-drug-discovery-and-development https://www.phenomixsciences.com/white-paper/the-case-for-smarter-glp-1-utilization-cost-coverage-and-clinical-outcomes-with-myphenomerx https://www.phenomixsciences.com/myphenomerx https://www.phenomixsciences.com/evidence/association-between-gastrointestinal-phenotypes-and-weight-gain-in-younger-adults-a-prospective-4-year-cohort-study https://www.phenomixsciences.com/evidence/changes-in-time-of-gastric-emptying-after-surgical-and-endoscopic-bariatrics-and-weight-loss-a-systematic-review-and-meta-analysis https://www.phenomixsciences.com/evidence/delayed-gastric-emptying-as-a-proposed-mechanism-of-action-during-intragastric-balloon-therapy-results-of-a-prospective-study https://www.phenomixsciences.com/evidence/effects-of-liraglutide-on-weight-satiation-and-gastric-functions-in-obesity-a-randomised-placebo-controlled-pilot-trial https://www.phenomixsciences.com/evidence/endoscopic-sleeve-gastroplasty-alters-gastric-physiology-and-induces-loss-of-body-weight-in-obese-individuals https://www.phenomixsciences.com/evidence/exenatide-in-obesity-with-accelerated-gastric-emptying-a-randomized-pharmacodynamics-study https://www.phenomixsciences.com/evidence/food-intake-regulation-relevance-to-bariatric-and-metabolic-endoscopic-therapies https://www.phenomixsciences.com/evidence/gastrointestinal-traits-individualizing-therapy-for-obesity-with-drugs-and-devices https://www.phenomixsciences.com/evidence/genetic-and-physiological-insights-into-satiation-variability-predict-responses-to-obesity-treatment https://www.phenomixsciences.com/evidence/pharmacogenomics-of-medication-induced-weight-gain-and-antiobesity-medications https://www.phenomixsciences.com/evidence/phenotype-tailored-lifestyle-intervention-on-weight-loss-and-cardiometabolic-risk-factors-in-adults-with-obesity-a-single-centre-non-randomised-proof-of-concept-study https://www.phenomixsciences.com/evidence/physical-activity-is-associated-with-accelerated-gastric-emptying-and-increased-ghrelin-in-obesity https://www.phenomixsciences.com/evidence/precision-medicine-for-obesity https://www.phenomixsciences.com/evidence/precision-medicine-in-obesity-applying-oncologys-lessons-to-transform-drug-discovery-and-development https://www.phenomixsciences.com/evidence/quantitative-gastrointestinal-and-psychological-traits-associated-with-obesity-and-response-to-weight-loss-therapy https://www.phenomixsciences.com/evidence/selection-of-antiobesity-medications-based-on-phenotypes-enhances-weight-loss-a-pragmatic-trial-in-an-obesity-clinic https://www.phenomixsciences.com/evidence/the-case-for-smarter-glp-1-utilization-cost-coverage-and-clinical-outcomes-with-myphenomerx https://www.phenomixsciences.com/evidence-topics/lifestyle https://www.phenomixsciences.com/evidence-topics/medications https://www.phenomixsciences.com/evidence-topics/phenotyping https://www.phenomixsciences.com/evidence-topics/procedures https://www.phenomixsciences.com/company/team/andres-acosta-md-phd https://www.phenomixsciences.com/company/team/liv-williamsen https://www.phenomixsciences.com/company/team/mark-bagnall https://www.phenomixsciences.com/company/team/michael-camilleri-md https://www.phenomixsciences.com/company/team/tim-oconnor https://www.phenomixsciences.com/company/media-and-press/5-interesting-companies-i-saw-at-hlth https://www.phenomixsciences.com/company/media-and-press/a-genetic-test-may-predict-which-weight-loss-drugs-work-best-for-patients https://www.phenomixsciences.com/company/media-and-press/can-a-test-tell-me-if-wegovy-or-zepbound-will-work-for-me https://www.phenomixsciences.com/company/media-and-press/duly-health-brings-genetic-based-weight-loss-treatment-to-chicago-with-myphenome-test https://www.phenomixsciences.com/company/media-and-press/emotional-hunger-in-obesity-predicted-with-gene-risk-score https://www.phenomixsciences.com/company/media-and-press/in-the-era-of-blockbuster-obesity-drugs-a-personalized-approach-could-boost-outcomes https://www.phenomixsciences.com/company/media-and-press/more-patients-open-to-non-glp-1-obesity-treatments-after-learning-about-alternatives-phenomix-survey-finds https://www.phenomixsciences.com/company/media-and-press/more-than-half-of-glp-1-users-reported-seeking-follow-up-care-for-side-effects-phenomix-sciences-report-finds https://www.phenomixsciences.com/company/media-and-press/myphenome-test-earns-spot-on-times-2024-best-inventions https://www.phenomixsciences.com/company/media-and-press/myphenome-test-shows-promise-in-predicting-weight-gain-highlighting-need-for-early-intervention-in-obesity https://www.phenomixsciences.com/company/media-and-press/new-mayo-clinic-studies-find-myphenome-test-predicts-recurrent-weight-regain-after-bariatric-surgery https://www.phenomixsciences.com/company/media-and-press/new-phenotyping-tests-slay-obesity-myths https://www.phenomixsciences.com/company/media-and-press/new-research-from-phenomix-sciences-identifies-biological-signal-associated-with-emotional-hunger-phenotype https://www.phenomixsciences.com/company/media-and-press/new-survey-shows-strong-patient-support-for-personalized-obesity-interventions https://www.phenomixsciences.com/company/media-and-press/not-everyone-loses-weight-on-ozempic https://www.phenomixsciences.com/company/media-and-press/novel-gene-risk-score-predicts-outcomes-after-rygb-surgery https://www.phenomixsciences.com/company/media-and-press/novel-gene-risk-score-predicts-outcomes-after-rygb-surgery-2 https://www.phenomixsciences.com/company/media-and-press/people-who-dont-lose-weight-on-wegovy-may-have-genetic-differences https://www.phenomixsciences.com/company/media-and-press/phenomix-and-mayo-clinic-publish-research-demonstrating-utility-of-myphenome-test-for-personalized-glp-1-and-phen-top-treatment https://www.phenomixsciences.com/company/media-and-press/phenomix-sciences-and-informeddna-partner-to-advance-genetics-driven-obesity-care https://www.phenomixsciences.com/company/media-and-press/phenomix-sciences-announces-first-prospective-clinical-study-of-semaglutide-using-myphenome-tm-test https://www.phenomixsciences.com/company/media-and-press/phenomix-sciences-co-founders-awarded-first-patent-for-using-precision-medicine-and-phenotyping-to-treat-obesity https://www.phenomixsciences.com/company/media-and-press/phenomix-sciences-expands-evidence-for-myphenome-tm-test-predicting-glp-1-response-and-obesity-risk-in-large-diverse-populations https://www.phenomixsciences.com/company/media-and-press/phenomix-sciences-report-finds-patients-see-glp-1s-as-progress-not-a-cure-want-more-guidance-on-long-term-care https://www.phenomixsciences.com/company/media-and-press/precision-medicine-for-weight-loss-dr-andres-acosta https://www.phenomixsciences.com/company/media-and-press/the-problem-with-ozempic https://www.phenomixsciences.com/company/media-and-press/time-magazine-a-new-test-predicts-who-will-benefit-most-from-weight-loss-drugs https://www.phenomixsciences.com/company/media-and-press/what-is-your-obesity-type-this-could-change-everything-with-dr-andres-acosta https://www.phenomixsciences.com/company/media-and-press/when-weight-loss-drugs-dont-work https://www.phenomixsciences.com/company/media-and-press/why-do-a-significant-number-of-glp-1-users-stop-taking-the-medication-in-the-first-year https://www.phenomixsciences.com/media-and-press-types/article https://www.phenomixsciences.com/media-and-press-types/podcast https://www.phenomixsciences.com/media-and-press-types/press-release https://www.phenomixsciences.com/media-and-press-types/webinar